These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24922583)

  • 1. Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
    Zheng J; Yang Z; Li X; Li L; Ma H; Wang M; Zhang H; Zhen X; Zhang X
    ACS Chem Neurosci; 2014 Aug; 5(8):674-82. PubMed ID: 24922583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a New Series of Potent Adenosine A
    Yang Z; Li L; Zheng J; Ma H; Tian S; Li J; Zhang H; Zhen X; Zhang X
    ACS Chem Neurosci; 2016 Nov; 7(11):1575-1584. PubMed ID: 27569066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease.
    Atack JR; Shook BC; Rassnick S; Jackson PF; Rhodes K; Drinkenburg WH; Ahnaou A; Te Riele P; Langlois X; Hrupka B; De Haes P; Hendrickx H; Aerts N; Hens K; Wellens A; Vermeire J; Megens AA
    ACS Chem Neurosci; 2014 Oct; 5(10):1005-19. PubMed ID: 25203719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.
    Slee DH; Zhang X; Moorjani M; Lin E; Lanier MC; Chen Y; Rueter JK; Lechner SM; Markison S; Malany S; Joswig T; Santos M; Gross RS; Williams JP; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Wen J; O'Brien Z; Saunders J
    J Med Chem; 2008 Feb; 51(3):400-6. PubMed ID: 18189346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
    Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
    PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
    Shook BC; Rassnick S; Osborne MC; Davis S; Westover L; Boulet J; Hall D; Rupert KC; Heintzelman GR; Hansen K; Chakravarty D; Bullington JL; Russell R; Branum S; Wells KM; Damon S; Youells S; Li X; Beauchamp DA; Palmer D; Reyes M; Demarest K; Tang Y; Rhodes K; Jackson PF
    J Med Chem; 2010 Nov; 53(22):8104-15. PubMed ID: 20973483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
    Stasi MA; Minetti P; Lombardo K; Riccioni T; Caprioli A; Vertechy M; Di Serio S; Pace S; Borsini F
    Eur J Pharmacol; 2015 Aug; 761():353-61. PubMed ID: 25936513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
    Smith KM; Browne SE; Jayaraman S; Bleickardt CJ; Hodge LM; Lis E; Yao L; Rittle SL; Innocent N; Mullins DE; Boykow G; Reynolds IJ; Hill D; Parker EM; Hodgson RA
    Eur J Pharmacol; 2014 Apr; 728():31-8. PubMed ID: 24486705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
    Pinna A; Bonaventura J; Farré D; Sánchez M; Simola N; Mallol J; Lluís C; Costa G; Baqi Y; Müller CE; Cortés A; McCormick P; Canela EI; Martínez-Pinilla E; Lanciego JL; Casadó V; Armentero MT; Franco R
    Exp Neurol; 2014 Mar; 253():180-91. PubMed ID: 24412491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Aminopyrimidines as dual adenosine A1/A2A antagonists.
    Robinson SJ; Petzer JP; Terre'Blanche G; Petzer A; van der Walt MM; Bergh JJ; Lourens AC
    Eur J Med Chem; 2015 Nov; 104():177-88. PubMed ID: 26462195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiparkinsonian effects of novel adenosine A(2A) receptor antagonists.
    Drabczyńska A; Zygmunt M; Sapa J; Filipek B; Müller CE; Kieć-Kononowicz K
    Arch Pharm (Weinheim); 2011 Jan; 344(1):20-7. PubMed ID: 21213348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's disease.
    Shook BC; Rassnick S; Wallace N; Crooke J; Ault M; Chakravarty D; Barbay JK; Wang A; Powell MT; Leonard K; Alford V; Scannevin RH; Carroll K; Lampron L; Westover L; Lim HK; Russell R; Branum S; Wells KM; Damon S; Youells S; Li X; Beauchamp DA; Rhodes K; Jackson PF
    J Med Chem; 2012 Feb; 55(3):1402-17. PubMed ID: 22239465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preladenant, a novel adenosine A(2A) receptor antagonist for the potential treatment of parkinsonism and other disorders.
    Salamone JD
    IDrugs; 2010 Oct; 13(10):723-31. PubMed ID: 20878595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.
    Zhang X; Rueter JK; Chen Y; Moorjani M; Lanier MC; Lin E; Gross RS; Tellew JE; Williams JP; Lechner SM; Markison S; Joswig T; Malany S; Santos M; Castro-Palomino JC; Crespo MI; Prat M; Gual S; Díaz JL; Saunders J; Slee DH
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1778-83. PubMed ID: 18329269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
    Shiozaki S; Ichikawa S; Nakamura J; Kitamura S; Yamada K; Kuwana Y
    Psychopharmacology (Berl); 1999 Nov; 147(1):90-5. PubMed ID: 10591873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
    Carta AR; Pinna A; Tronci E; Morelli M
    Neurology; 2003 Dec; 61(11 Suppl 6):S39-43. PubMed ID: 14663008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
    Chen JF; Fredduzzi S; Bastia E; Yu L; Moratalla R; Ongini E; Schwarzschild MA
    Neurology; 2003 Dec; 61(11 Suppl 6):S74-81. PubMed ID: 14663016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
    Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
    Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
    Jones CK; Bubser M; Thompson AD; Dickerson JW; Turle-Lorenzo N; Amalric M; Blobaum AL; Bridges TM; Morrison RD; Jadhav S; Engers DW; Italiano K; Bode J; Daniels JS; Lindsley CW; Hopkins CR; Conn PJ; Niswender CM
    J Pharmacol Exp Ther; 2012 Feb; 340(2):404-21. PubMed ID: 22088953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A
    Basu S; Barawkar DA; Thorat S; Shejul YD; Patel M; Naykodi M; Jain V; Salve Y; Prasad V; Chaudhary S; Ghosh I; Bhat G; Quraishi A; Patil H; Ansari S; Menon S; Unadkat V; Thakare R; Seervi MS; Meru AV; De S; Bhamidipati RK; Rouduri SR; Palle VP; Chug A; Mookhtiar KA
    J Med Chem; 2017 Jan; 60(2):681-694. PubMed ID: 28055204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.